Veracyte: Core Growth Funds Prosigna And TrueMRD

Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion. Valuation premium is justified by operational leverage, self-funded pipeline expansion, and the durability of Veracyte’s evidence-based competitive moat.

I believe Veracyte ( VCYT ) is now transitioning from a 2-product genomic testing business into a self-funded cancer diagnostic platform. The company's clinical evidence, its specialist relationships, and its reimbursement infrastructure all reinforce one another.